<DOC>
	<DOCNO>NCT01020539</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation ( AlloSCT ) follow target immune therapy Gemtuzumab Ozogamicin patient acute myeloid leukemia ( AML ) /juvenile myelomonocytic leukemia ( JMML ) /myelodysplastic syndrome ( MDS ) safe well tolerate .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia</brief_title>
	<detailed_description>Gemtuzumab Ozogamicin ( CMA-676 ) chemotherapeutic agent consist recombinant humanize anti-CD33 antibody conjugate calicheamicin , highly potent cytotoxic antitumor antibiotic . The antibody portion Gemtuzumab bind specifically CD33 antigen , sialic acid-dependent adhesion protein express surface leukemic blast , normal leukemic myeloid colony-forming cell , include leukemic clonogenic precursor , exclude pluripotent hematopoietic stem cell nonhematopoietic cell . This result formation complex internalize , upon calicheamicin derivative release within lysosome myeloid cell . The free calicheamicin derivative bind deoxyribonucleic acid ( DNA ) , result DNA double strand break consequential cell death . Over 80 % AML patient possess myeloid blast cell CD33 surface antigen expression .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Disease Status AML 1st CR match family donor ( exclude Downs Syndrome , APL , poor cytogenetics [ 12p , 5q , 7 FLT3 mutation duplication ( 9 ; 11 ) others ] ) patient consent registered upfront AML COG study match family donor ) AML 1st CR [ exclude Downs Syndrome , APL , chromosome translocation ( 8 ; 21 ) inversion ( 16 ) poor cytogenetics ( 12p , 5q , 7 , FLT3 mutation duplication ( 9 ; 11 ) others ) ] unrelated donor AML 2nd CR Myelodysplastic Syndrome ( MDS ) ≤ 5 % bone marrow myeloblast diagnosis ( de novo patient ) Juvenile Myelomonocytic Leukemia ( JMML ) ≤ 5 % bone marrow myeloblast diagnosis In regard disease immunophenotype , disease must express minimum ≥10 % CD33 positivity patient AML Organ Function : Patients must adequate organ function define : Adequate renal function define : Serum creatinine &lt; 1.5 x normal , Creatinine clearance radioisotope glomerular filtration rate ( GFR ) 40 ml/min/m2 &gt; 60 ml/min/1.73 m2 equivalent GFR determine institutional normal range Adequate liver function define total bilirubin 2.0 x upper limit normal ( ULN ) , serum glutamicoxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase ( AST ) ) serum glutamicpyruvic transaminase ( SGPT ) ( alanine aminotransferase ( ALT ) ) &lt; 5.0 xULN Adequate cardiac function define : Shortening fraction ≥ 25 % echocardiogram , Ejection fraction ≥ 45 % radionuclide angiogram echocardiogram Adequate pulmonary function define : Diffusion capacity lung carbon monoxide ( DLCO ) ≥ 40 % pulmonary function test ( PFT ) ( Uncorrected ) For child uncooperative , evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 94 % room air Patients active central nervous system ( CNS ) AML/JMML disease time preparative regimen Secondary MDS Poor cytogenetics ( 12p , 5q , 7 , FLT3 mutation duplication ) Female patient pregnant ( positive human chorionic gonadotropin ( hCG ) ) Karnofsky &lt; 70 % Lansky &lt; 50 % 10 year less Age &gt; 30 year Seropositive Human Immunodeficiency Virus ( HIV ) Patients consent register upfront Children 's Oncology Group ( COG ) AML study match family donor</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
	<keyword>Targeted Immune Therapy</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Juvenile Myelomonocytic Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>JMML</keyword>
</DOC>